Atenolol pharmacology
Pro Research Analysisby 
Searched over 200M research papers for "atenolol pharmacology"
Atenolol Pharmacology: Mechanism of Action and Beta-Blockade
Atenolol is a selective beta-1 adrenoceptor antagonist, commonly known as a cardioselective beta-blocker. It works by blocking beta-1 receptors in the heart, which reduces heart rate and blood pressure, making it effective for treating hypertension, angina, and certain arrhythmias Conway1976Wadworth1991. Atenolol’s beta-blocking effect is primarily due to its (S)-enantiomer, as the (R)-enantiomer does not contribute significantly to its pharmacological action . The drug’s ability to reduce exercise-induced tachycardia and antagonize the effects of isoprenaline confirms its beta-blocking properties in humans Brown1976Conway1976Amery1977.
Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion
Atenolol is incompletely absorbed after oral administration, with bioavailability ranging from about 50% to 63% Wan1979Brown1976Reeves1978. Peak plasma concentrations are typically reached within 2–3 hours after oral dosing Brown1976Conway1976. The drug exhibits dose-independent pharmacokinetics, and its plasma elimination half-life ranges from approximately 6 to 9 hours in healthy individuals Wan1979Brown1976Conway1976. Atenolol is minimally metabolized in the body, with most of the drug excreted unchanged in the urine; about 50% of an oral dose and nearly 100% of an intravenous dose are recovered in urine Brown1976Reeves1978. In patients with renal impairment, the elimination half-life is prolonged, indicating the importance of renal function in atenolol clearance Wan1979Amery1977.
Clinical Effects and Therapeutic Use
Atenolol effectively lowers blood pressure and heart rate, with reductions in these parameters proportional to the dose or plasma concentration Wan1979Brown1976Wadworth1991. It is as effective as other beta-blockers and antihypertensive agents in managing hypertension and is also used for angina and arrhythmias . The drug is well tolerated, with a lower incidence of central nervous system side effects compared to less selective beta-blockers like propranolol, due to its low lipid solubility and limited brain penetration . Atenolol is also used in acute and long-term management of myocardial infarction, where it has been associated with reduced cardiovascular mortality .
Factors Influencing Pharmacological Response
The antihypertensive effect of atenolol can be influenced by other medications. For example, indomethacin, a nonsteroidal anti-inflammatory drug, can reduce atenolol’s blood pressure-lowering effect, possibly by interfering with prostaglandin synthesis, while sulindac does not have this effect . The degree of beta-blockade correlates with blood levels of atenolol, but the hypotensive effect does not always show a close correlation with plasma concentration . Body weight and renal function also affect atenolol blood levels and pharmacological response .
Bioequivalence and Safety
Atenolol tablets have been shown to be bioequivalent in different populations and under both fasting and fed conditions, with similar pharmacokinetic profiles and no serious adverse events reported in healthy volunteers . Most adverse reactions are mild and do not lead to discontinuation of therapy Li2024Wadworth1991.
Conclusion
Atenolol is a well-established, cardioselective beta-blocker with predictable pharmacokinetics and a strong safety profile. Its primary action is to block beta-1 receptors in the heart, leading to reduced heart rate and blood pressure. The drug is minimally metabolized and mainly excreted unchanged in urine, making renal function an important consideration in dosing. Atenolol remains a mainstay in the treatment of hypertension, angina, arrhythmias, and in the prevention of cardiovascular events.
Sources and full results
Most relevant research papers on this topic